Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
vii. lappuse
... ment Manual , the Federal Register , Public Laws , Weekly Compilation of Presi- dential Documents and the Privacy Act Compilation are available in electronic format at www.access.gpo.gov/nara ( “ GPO Access ” ) . For more information ...
... ment Manual , the Federal Register , Public Laws , Weekly Compilation of Presi- dential Documents and the Privacy Act Compilation are available in electronic format at www.access.gpo.gov/nara ( “ GPO Access ” ) . For more information ...
12. lappuse
... ment . Any drug limited to prescription use under section 503 ( b ) ( 1 ) ( C ) of the act remains so limited until it is exempted as provided in paragraph ( b ) or ( e ) of this section . ( b ) Prescription - exemption procedure for ...
... ment . Any drug limited to prescription use under section 503 ( b ) ( 1 ) ( C ) of the act remains so limited until it is exempted as provided in paragraph ( b ) or ( e ) of this section . ( b ) Prescription - exemption procedure for ...
14. lappuse
... ment against use of the preparation in case of rectal bleeding , as this may in- dicate serious disease . ( 4 ) Phenyltoloxamine dihydrogen cit- rate ( N , N - dimethyl- ( a - phenyl - O - toloxy ) ethylamine dihydrogen citrate ) , prep ...
... ment against use of the preparation in case of rectal bleeding , as this may in- dicate serious disease . ( 4 ) Phenyltoloxamine dihydrogen cit- rate ( N , N - dimethyl- ( a - phenyl - O - toloxy ) ethylamine dihydrogen citrate ) , prep ...
33. lappuse
... ment that the drug product has been prescribed for the use of the patient and should not be used for other condi- tions or given to others , and a state- ment that the patient's pharmacist or practitioner has a more technical leaf- let ...
... ment that the drug product has been prescribed for the use of the patient and should not be used for other condi- tions or given to others , and a state- ment that the patient's pharmacist or practitioner has a more technical leaf- let ...
35. lappuse
... ment of pleural ef- fusions and / or as- cites . Interstitial treatment of cancer . Potassium space studies . Pancreas scans . Bone scans on pa- tients with diag- nosed cancer . Brain scans . Thyroid scans . Liver and spleen Blood pool ...
... ment of pleural ef- fusions and / or as- cites . Interstitial treatment of cancer . Potassium space studies . Pancreas scans . Bone scans on pa- tients with diag- nosed cancer . Brain scans . Thyroid scans . Liver and spleen Blood pool ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning